Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 20/20 | 0.55 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6199023 | 0.87 | UTS2R (0.58) | UTS2RADRA2ADRD2SLC6A2HTR2A | |
| SCHEMBL6194403 | 0.87 | UTS2R (0.61) | UTS2RADRA2ADRD2SLC6A2HTR2A | |
| SCHEMBL6215071 | 0.87 | UTS2R (0.59) | UTS2RADRA2ADRD2SLC6A2HTR2A | |
| SCHEMBL6195154 | 0.85 | UTS2R (0.61) | UTS2RADRA2ADRD2SLC6A2HTR2A | |
| SCHEMBL4857354 | 0.85 | UTS2R (0.61) | UTS2RADRA2ADRD2SLC6A2HTR2A | |
| SCHEMBL4858773 | 0.82 | UTS2R (0.62) | UTS2RADRA2ADRD2SLC6A2HTR2A | |
| SCHEMBL3560944 | 0.82 | UTS2R (0.62) | UTS2RADRA2ADRD2SLC6A2HTR2A | |
| SCHEMBL3566671 | 0.82 | UTS2R (0.61) | UTS2RADRA2ADRD2SLC6A2HTR2A | |
| SCHEMBL4854635 | 0.81 | UTS2R (0.62) | UTS2RADRA2ADRD2SLC6A2HTR2A | |
| SCHEMBL3565146 | 0.81 | UTS2R (0.63) | UTS2RADRA2ADRD2SLC6A2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7375227-B2 | Quinoline derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-05-20 | — | — | US | disclosed |
| EP-1499607-B1 | 4-(PIPERIDYL- AND PYRROLIDYL-ALKYL-UREIDO)-QUINOLINES AS UROTENSIN II RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2005-12-07 | — | — | EP | disclosed |
| US-20050043535-A1 | 4-(Piperidyl-and pyrrolidyl-alkyl-ureido)-quinolines as urotensin II receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2005-02-24 | — | — | US | disclosed |
| EP-1499607-A1 | 4-(PIPERIDYL- AND PYRROLIDYL-ALKYL-UREIDO)-QUINOLINES AS UROTENSIN II RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2005-01-26 | — | — | EP | disclosed |
| WO-2003048154-A1 | 4-(PIPERIDYL- AND PYRROLIDYL-ALKYL-UREIDO) -QUINOLINES AS UROTENSIN II RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043535-A1 | 4-(Piperidyl-and pyrrolidyl-alkyl-ureido)-quinolines as urotensin II receptor antagonists | UTS2R, NTSR2, PLAUR | UTS2R 1/4885ADRA2A 58/4885DRD2 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.